FDA has a legitimate role to play in slowing down the cost of developing drugs, and it can do so by relying on good regulatory science, the agency’s commissioner Scott Gottlieb said.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
